SAR442257, a CD38/CD28/CD3 trispecific antibody, potentiates CAR T‐cell activity against large B‐cell lymphoma
M. R. Green(The University of Texas MD Anderson Cancer Center), L. Wang(The University of Texas MD Anderson Cancer Center), Irtiza Sheikh(The University of Texas MD Anderson Cancer Center), Ashley Wilson(Center for Infectious Disease Research), Shahin Lockman(Brigham and Women's Hospital), Patrick K. Reville(The University of Texas MD Anderson Cancer Center), Erkuan Dai(Shanghai Jiao Tong University), Helgi van de Velde(Sanofi (Belgium)), J. Henderson(The University of Texas MD Anderson Cancer Center), Qing Deng(Central South University), S. G. Parsons, Kamlesh Bisht, Chizitara Okwuchi(The University of Texas MD Anderson Cancer Center), Hongfei Wang(University of California, Santa Barbara), Phillip Kim(Prometheus Biosciences (United States)), C. Le(The University of Texas MD Anderson Cancer Center), Sattva S. Neelapu(The University of Texas MD Anderson Cancer Center), Elizabeta A. Rojas(The University of Texas MD Anderson Cancer Center)
Cited by 2
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells
|Transplantation and Cellular Therapy|2018|3.6k
Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial
|The Lancet Oncology|2018|2.3k
Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium
|Journal of Clinical Oncology|2020|782